Symbicort in Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Registration Number
- NCT00611520
- Lead Sponsor
- AstraZeneca
- Brief Summary
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64730
Inclusion Criteria
- Patients with COPD treated with budesonide/formoterol
Read More
Exclusion Criteria
- limitations; possible risks; warnings; contraindications mentioned in the SPC.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method